EUVIMEDEUVIMED entdecken
Open Access

Soluble Signal Inhibitory Receptor on Leukocytes-1 Is Released from Activated Neutrophils by Proteinase 3 Cleavage

Helen J von Richthofen iD, Geertje H A Westerlaken, Doron Gollnast, Sjanna Besteman, Eveline M Delemarre, Karlijn Rodenburg, Petra Moerer, Daphne A C Stapels iD, Anand K Andiappan iD, Olaf Rötzschke, Stefan Nierkens, Helen L Leavis und 3 weitere

The Journal of Immunology · 2023

DOI: 10.4049/jimmunol.2200169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Helen J von Richthofen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Bronchiolitis, COVID-19, Respiratory Syncytial Virus Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Signal inhibitory receptor on leukocytes-1 (SIRL-1) is an immune inhibitory receptor expressed on human granulocytes and monocytes that dampens antimicrobial functions. We previously showed that sputum neutrophils from infants with severe respiratory syncytial virus (RSV) bronchiolitis have decreased SIRL-1 surface expression compared with blood neutrophils and that SIRL-1 surface expression is rapidly lost from in vitro activated neutrophils. This led us to hypothesize that activated neutrophils lose SIRL-1 by ectodomain shedding. Here, we developed an ELISA and measured the concentration of soluble SIRL-1 (sSIRL-1) in patients with RSV bronchiolitis and hospitalized patients with COVID-19, which are both characterized by neutrophilic inflammation. In line with our hypothesis, sSIRL-1 concentration was increased in sputum compared with plasma of patients with RSV bronchiolitis and in serum of hospitalized patients with COVID-19 compared with control serum. In addition, we show that in vitro activated neutrophils release sSIRL-1 by proteolytic cleavage and that this diminishes the ability to inhibit neutrophilic reactive oxygen species production via SIRL-1. Finally, we found that SIRL-1 shedding is prevented by proteinase 3 inhibition and by extracellular adherence protein from Staphylococcus aureus. Notably, we recently showed that SIRL-1 is activated by PSMα3 from S. aureus, suggesting that S. aureus may counteract SIRL-1 shedding to benefit from preserved inhibitory function of SIRL-1. In conclusion, we report that SIRL-1 is released from activated neutrophils by proteinase 3 cleavage and that endogenous sSIRL-1 protein is present in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BronchiolitisCOVID-19Respiratory Syncytial Virus InfectionsHumansInfantMyeloblastinNeutrophilsReceptors, ImmunologicStaphylococcus aureusLeukocytes

Substanzen

MyeloblastinReceptors, Immunologic

Autor:innen und Institutionen

  • Center of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Oncode Institute, Utrecht, the Netherlands.
  • Department of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Singapore Immunology Network, Agency for Science, Technology and Research, Singapore; and.
  • Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

ORCID-Profile: Helen J von Richthofen, Daphne A C Stapels, Anand K Andiappan, Suzan H M Rooijakkers, Linde Meyaard

Förderung

  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • ZonMw

Zitieren

APA

von Richthofen, H. J., Westerlaken, G. H. A., Gollnast, D., Besteman, S., Delemarre, E. M., Rodenburg, K., Moerer, P., Stapels, D. A. C., Andiappan, A. K., Rötzschke, O., Nierkens, S., Leavis, H. L., Bont, L. J., Rooijakkers, S. H. M., & Meyaard, L. (2023). Soluble Signal Inhibitory Receptor on Leukocytes-1 Is Released from Activated Neutrophils by Proteinase 3 Cleavage. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2200169

Vancouver

von Richthofen HJ, Westerlaken GHA, Gollnast D, Besteman S, Delemarre EM, Rodenburg K, et al. Soluble Signal Inhibitory Receptor on Leukocytes-1 Is Released from Activated Neutrophils by Proteinase 3 Cleavage. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2200169

BibTeX
@article{vonRichthofen2023,
  author = {von Richthofen, Helen J and Westerlaken, Geertje H A and Gollnast, Doron and Besteman, Sjanna and Delemarre, Eveline M and Rodenburg, Karlijn and Moerer, Petra and Stapels, Daphne A C and Andiappan, Anand K and Rötzschke, Olaf and Nierkens, Stefan and Leavis, Helen L and Bont, Louis J and Rooijakkers, Suzan H M and Meyaard, Linde},
  title = {Soluble Signal Inhibitory Receptor on Leukocytes-1 Is Released from Activated Neutrophils by Proteinase 3 Cleavage},
  journal = {The Journal of Immunology},
  year = {2023},
  doi = {10.4049/jimmunol.2200169}
}
Kostenlos starten →